rs1008899 — NEDD4L

Intronic NEDD4L variant tagging isoforms with differing ENaC ubiquitination capacity; the G allele associates with reduced blood pressure response to thiazide diuretics and salt-sensitive hypertension risk

See your personal result for NEDD4L

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NEDD4L and Salt-Sensitive Hypertension — The Sodium Disposal Gene

Every time you eat a salty meal, your kidneys face a choice: retain that sodium or excrete it. The NEDD4L gene sits at the heart of this decision. It encodes NEDD4L (Neural Precursor Cell-Expressed Developmentally Downregulated 4-Like)11 NEDD4L (Neural Precursor Cell-Expressed Developmentally Downregulated 4-Like)
an E3 ubiquitin ligase that tags ENaC sodium channels for destruction in the kidney's collecting duct cells. When NEDD4L works well, it constantly prunes excess ENaC from the cell surface, keeping sodium reabsorption — and blood pressure — in check. When NEDD4L function is reduced, ENaC accumulates at the membrane, sodium floods back into the bloodstream, and blood pressure climbs.

The Mechanism

The rs1008899 variant sits deep within intron 1 of NEDD4L on chromosome 18q21 — not a coding change, but a tag for underlying regulatory or isoform-switching differences in the gene. NEDD4L produces multiple protein isoforms depending on which exons are included during splicing. The key isoform distinction involves the C2 domain22 C2 domain
a calcium-dependent lipid-binding module that controls NEDD4L's subcellular targeting and interaction strength with ENaC.

NEDD4L exerts its blood pressure effect through a precisely regulated chain: it ubiquitinates the PY motif of ENaC's beta and gamma subunits, triggering endocytosis and lysosomal degradation of the channel. Less ENaC at the apical membrane of collecting duct cells means less sodium reabsorption and lower blood volume. The G allele at rs1008899, which is in strong LD with rs292449 (D′=0.908, r²=0.533) but independent of the rs4149601 splice-site variant (D′<0.3, r²<0.1), tags a haplotype state associated with reduced ENaC ubiquitination efficiency — not through the C2-domain splice mechanism, but through a distinct regulatory locus.

This pathway is also regulated by WNK1 kinase33 regulated by WNK1 kinase
WNK1 phosphorylates NEDD4L, modulating its ability to ubiquitinate ENaC; variants in the ADD1-WNK1-NEDD4L axis interact to determine individual sodium sensitivity.

The Evidence

The clearest evidence comes from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) trial44 Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) trial
McDonough et al., J Hypertens 2013, which genotyped rs1008899 alongside three other NEDD4L variants in 767 hypertensive patients (465 white, 302 African-American). Among white patients treated with hydrochlorothiazide (HCTZ), rs1008899 showed significant associations with blood pressure response — with A-allele carriers achieving greater reductions in both systolic and diastolic blood pressure. Associations remained significant after adjusting for the independent rs4149601 signal, confirming rs1008899 captures independent variance in HCTZ response. No associations were detected in African-Americans or with atenolol treatment, underscoring the variant's specificity to thiazide-sensitive, sodium-channel-mediated pathways in European-ancestry populations.

Salt-sensitivity experiments in a Swedish crossover trial of 39 normotensive subjects55 Swedish crossover trial of 39 normotensive subjects
Dahlberg et al., PLoS One 2007 demonstrated that NEDD4L GG homozygotes at rs4149601 (the functional splice variant in high LD with rs292449 but not rs1008899) showed a systolic blood pressure shift of 18 mmHg on high-salt versus low-salt diet, compared to only 6 mmHg in AA carriers (P=0.007). Plasma renin, a marker of sodium excess, was correspondingly suppressed. The G-allele landscape across NEDD4L consistently marks individuals who retain sodium less efficiently when salt intake rises.

Long-term cardiovascular consequences were established in the Malmö Diet and Cancer cohort (n=27,564)66 Malmö Diet and Cancer cohort (n=27,564)
Dahlberg et al., J Hypertens 2014, where the NEDD4L salt-sensitivity genotype carried a cardiovascular disease hazard ratio of 1.13 (95% CI 1.02–1.25, P=0.018) and coronary event HR 1.20 (95% CI 1.06–1.37, P=0.005) independent of blood pressure at baseline — suggesting NEDD4L-mediated sodium dysregulation has effects beyond simple blood pressure elevation.

Practical Actions

For GG homozygotes, the most important implication is pharmacogenomic: the standard first-line antihypertensive thiazide diuretic (HCTZ) may not lower blood pressure as effectively as in A-allele carriers. If you have hypertension and carry the GG genotype, discussing alternative or add-on antihypertensives (ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists like spironolactone) with your prescriber is clinically relevant. Sodium restriction is particularly important because your ENaC system is less effectively downregulated — the kidney is slower to excrete a sodium load.

Heterozygous AG carriers occupy an intermediate position: their HCTZ response is better than GG but less robust than AA homozygotes.

Interactions

rs1008899 is in strong LD with rs292449 (D′=0.908, r²=0.533), so these two variants largely track together. The related rs4149601 functional variant (which directly alters NEDD4L splicing and C2-domain inclusion) represents an independent, stronger signal. Individuals carrying risk haplotypes at both rs1008899/rs292449 AND rs4149601 may have compounded sodium retention.

Interaction studies with ADD1 (alpha-adducin, rs4961) and WNK1 show that the sodium-handling effect of NEDD4L variants is amplified when combined with sodium-retaining ADD1 variants — individuals carrying risk genotypes at multiple nodes of the ENaC-regulation axis have the highest salt sensitivity and the greatest pharmacogenomic response to sodium-targeted therapy.

Drug Interactions

hydrochlorothiazide reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Enhanced Diuretic Responder Beneficial

Your NEDD4L genotype is associated with improved blood pressure response to thiazide diuretics

You carry two copies of the A allele at rs1008899, the rarer genotype found in about 7% of Europeans. This genotype tags a NEDD4L haplotype state associated with more effective ENaC downregulation in the kidney's collecting duct. In clinical trials of hypertensive patients, AA-allele carriers showed the greatest blood pressure reduction on hydrochlorothiazide treatment, with roughly 6 mmHg greater systolic reduction compared to GG carriers. Your kidneys appear better equipped to excrete a sodium load through more active ENaC ubiquitination, which translates to lower salt sensitivity and more robust response to thiazide-class antihypertensives.

AG Intermediate Diuretic Responder Intermediate

Moderate NEDD4L-related variation in sodium handling and thiazide response

You carry one copy of the G allele and one copy of the A allele at rs1008899, the most common genotype found in approximately 38% of people globally. Your blood pressure response to thiazide diuretics falls between the two homozygous groups — better than GG carriers but not as robust as AA homozygotes. Your kidneys' ability to downregulate ENaC sodium channels has partial genetic support, and your salt sensitivity is moderately elevated relative to AA carriers.

GG Reduced Diuretic Responder Reduced

NEDD4L variant associated with reduced thiazide diuretic response and higher salt sensitivity

NEDD4L's role is to ubiquitinate and degrade ENaC (epithelial sodium channel) subunits at the collecting duct apical membrane. When this process is impaired, ENaC accumulates at the surface and drives sodium reabsorption into the bloodstream, raising blood volume and pressure. The G allele at rs1008899 tags a NEDD4L regulatory state where this downregulation is less effective.

The clinical consequence is twofold. First, salt sensitivity: studies of NEDD4L G-allele haplotypes showed systolic blood pressure shifts of up to 18 mmHg between high-salt and low-salt dietary conditions, versus only 6 mmHg in protective-allele carriers (P=0.007). Second, pharmacogenomics: thiazide diuretics work partly by reducing sodium reabsorption in the distal tubule, upstream of where NEDD4L acts. When ENaC compensation downstream is robust (as in GG carriers), thiazide efficacy is partially offset. Renin-angiotensin system agents and mineralocorticoid receptor antagonists that act more directly on the aldosterone-ENaC axis may be pharmacologically better matched to this genotype.

The long-term cardiovascular stakes are real: in a Swedish cohort of 27,564 people, the NEDD4L sodium-retention genotype combination was associated with a cardiovascular disease hazard ratio of 1.13 and coronary event risk of 1.20, partly blood pressure-independent, suggesting ENaC dysregulation has systemic consequences beyond simple BP elevation.